Cash

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, April 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

THE INNOVATIVE DIRECT-TO-CONSUMER MUSIC PLATFORM ANNOUNCES PUBLIC LAUNCH

Retrieved on: 
Tuesday, April 9, 2024
Cash, WeChat, News, Alipay, Music, IOS, Android, Billboard

NEW YORK, April 9, 2024 /PRNewswire/ -- EVEN, the pioneering direct-to-consumer music platform announces its official launch of EVEN after year of Beta. Alongside this news, EVEN also released its iOS and Android mobile app and announced news that sales on EVEN will report to Luminate, making them the first superfan app to count sales towards Billboard charting. Founded by music industry veteran Mag Rodriguez, EVEN is on a mission to empower artists and fans to invest in each other, ushering in a new landscape where artists can make money from their music.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- EVEN, the pioneering direct-to-consumer music platform announces its official launch of EVEN after year of Beta.
  • Founded by music industry veteran Mag Rodriguez, EVEN is on a mission to empower artists and fans to invest in each other, ushering in a new landscape where artists can make money from their music.
  • With this launch EVEN introduces a series of features and partnerships aimed at enhancing the music ecosystem for artists and fans alike:
    A Mobile App: where fans can directly engage with their favorite artists, chat with fellow music lovers, and enjoy offline access to a vast library of purchased music.
  • With this public launch, EVEN continues to assist artists to monetize their art and get closer to their fans.

Stoke Space Names Retired U.S. Space Force Lt. Gen. John E. Shaw to Board of Directors, Paul Croci as Chief Financial Officer

Retrieved on: 
Monday, April 8, 2024
United States Space Force, Citigroup, United, Ground Intelligence Officer, Paul's walk, Space Operations Command, Growth, Astronautics, Vandenberg Space Force Base, Mechanical engineering, George Washington University, Aerospace, Honeywell, Policy, University, Fourteenth Air Force, Stoke Space, United States Air Force, Air force, Initial public offering, Cash, United States Space Command, Navy, Barclays, General Shaw, Lapsa, Management

KENT, Wash., April 8, 2024 /PRNewswire/ -- Today Stoke Space announced that the company has appointed retired U.S. Space Force Lt. Gen. John E. Shaw to its Board of Directors and Paul Croci as its chief financial officer.

Key Points: 
  • KENT, Wash., April 8, 2024 /PRNewswire/ -- Today Stoke Space announced that the company has appointed retired U.S. Space Force Lt. Gen. John E. Shaw to its Board of Directors and Paul Croci as its chief financial officer.
  • In this role, Shaw advocated for the U.S. Space Force to pursue advanced capabilities that enable dynamic space operations in which in-space assets can actively maneuver without constraint.
  • "Stoke Space is a highly innovative and motivated team with a compelling vision for reusable and sustainable space capabilities," Shaw said.
  • "It is an incredibly exciting opportunity as Stoke Space is well positioned to grow rapidly in the emerging new space economy."

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

Retrieved on: 
Tuesday, March 19, 2024
KNTE, Cash, Acquisition, Treasury, Sale, CVR, Security (finance)

On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).

Key Points: 
  • On March 4, 2024, XOMA commenced a tender offer to acquire all outstanding shares of Kinnate common stock (“the Offer”).
  • Pursuant to the terms of the Merger Agreement, based upon Kinnate’s estimated calculation of cash, net of transaction costs, wind-down costs and other liabilities at closing, the additional cash amount has been determined to be the maximum $0.2527 per share.
  • Therefore, the Cash Amount that Kinnate stockholders will receive in the Offer is $2.5879 per share.
  • As previously announced, Kinnate stockholders holding approximately 46% of Kinnate common stock have signed support agreements to tender their shares in the Offer prior to the expiration date and support the merger.

ZeroFox Announces Fourth Quarter and Fiscal Year 2024 Financial Results

Retrieved on: 
Friday, March 15, 2024
Growth, Intelligence, OPM, Cash, Revenue stream, ZeroFox, Software, Annual report, GAAP, Human

WASHINGTON, March 15, 2024 (GLOBE NEWSWIRE) -- ZeroFox Holdings, Inc. (Nasdaq: ZFOX), an enterprise software-as-a-service leader in external cybersecurity, today announced financial results for the fourth quarter and fiscal year ended January 31, 2024.

Key Points: 
  • WASHINGTON, March 15, 2024 (GLOBE NEWSWIRE) -- ZeroFox Holdings, Inc. (Nasdaq: ZFOX), an enterprise software-as-a-service leader in external cybersecurity, today announced financial results for the fourth quarter and fiscal year ended January 31, 2024.
  • “Q4 was another positive quarter for ZeroFox with sustained top line growth and positive free cash flow” said James C. Foster.
  • Given the transaction with Haveli Investments, ZeroFox will not be hosting an earnings conference call or live webcast to discuss its fourth quarter and fiscal year 2024 financial results and ZeroFox will not be providing guidance for the first quarter or full fiscal year 2025.
  • For further detail and discussion of ZeroFox’s financial performance please refer to ZeroFox’s Annual Report on Form 10-K for the fiscal year ended January 31, 2024.

SatixFy Announces Full Year 2023 Results

Retrieved on: 
Friday, March 29, 2024
Technology, Hardware, Satellite, LEO, Research, European Space Agency, Device, MDA, Application-specific integrated circuit, Cash, Travel, SATX, Insurance, Marketing, Alta Partners, Investment, Research and development, Annual report, RSU, Cryptocurrency

SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.

Key Points: 
  • SatixFy Communications Ltd. (the “Company” or “SatixFy”) (NYSE AMERICAN: SATX), a pioneering force in next-generation satellite communication systems driven by in-house developed chipsets, has released its consolidated financial results for the full year period ended December 31, 2023.
  • The decrease in gross profit and margin due to the Company’s engagement in 2023 in projects which carry lower gross margins compared to 2022.
  • Nir Barkan, Acting Chief Executive Officer of SatixFy, commented, “2023 was marked by strategic advancements and solid progress within our product development and customer engagements.
  • “SatixFy is at a key inflection point in the industry, driven in-part by the fast-growing Low Earth Orbit ('LEO') low-latency satellite market providing broad data coverage anywhere, anytime.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Pacer ETFs Expands Cash Cows Series with Launch of Developed Markets Growth Leaders ETF

Retrieved on: 
Thursday, March 21, 2024
Banking, Asset Management, Professional Services, Finance, Partnership, Name, MSCI, Pacer, Cash

Pacer ETFs (“Pacer”), an ETF issuer focused on strategy-driven, rules-based ETFs, announces today the launch of the Pacer Developed Markets Cash Cows Growth Leaders ETF (NYSE: EAFG).

Key Points: 
  • Pacer ETFs (“Pacer”), an ETF issuer focused on strategy-driven, rules-based ETFs, announces today the launch of the Pacer Developed Markets Cash Cows Growth Leaders ETF (NYSE: EAFG).
  • The fund joins the firm’s successful Cash Cows fund family, a series of ETFs centered around free cash flow focused strategies.
  • EAFG’s strategy tracks the Pacer Developed Markets Cash Cows Growth Leaders Index, pulling the top 100 international large- and mid-cap securities in developed markets with above-average free cash flow margin from the MSCI EAFE Index.
  • “As markets have been impacted by elevated interest rates and geopolitical tensions, investors’ attention has shifted towards resilient strategies like the high free cash flow approach of our Cash Cows funds,” says Sean O’Hara, President of Pacer ETF Distributors.

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Toxicity, Administration, Information technology, MECP2, Inc., Patient, Cash, Batten disease, Cohort, Female, Insurance, Rett syndrome, Research and development, Investment, Clinical trial, Net, Data, DSM-IV codes, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates.
  • We believe this expanded dataset will support future regulatory discussions to align on the design of a potential registrational study,” said Rachel McMinn, Ph.D., Chief Executive Officer and Founder of Neurogene.
  • “NGN-401 has the potential to be a best-in-class treatment option with a targeted route of administration to deliver full-length, functional copies of the MECP2 gene.
  • Net income for the three months ended December 31, 2023 included a one-time $16.4 million bargain purchase gain related to the reverse merger.